Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024Nature CommunicationsOpen Access

A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAnne GM SchilderSWStephan WolpertSSShakeel R. Saeed

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schilder et al. (2024) studied this question.

synapsesocial.com/papers/68e7604eb6db6435876d767bhttps://doi.org/10.1038/s41467-024-45784-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adoption, use and non-use of hearing aids: a robust estimate based on Welsh national survey statistics2020 · 69 citations
  2. 2Hearing Protection, Restoration, and Regeneration: An Overview of Emerging Therapeutics for Inner Ear and Central Hearing Disorders2019 · 88 citations
  3. 3Efficacy and Safety of AM-111 in the Treatment of Acute Sensorineural Hearing Loss2014 · 93 citations
  4. 4Properties of auditory nerve responses in absence of outer hair cells1978 · 419 citations
  5. 5Adult normative data for the speech in babble (SiB) test2019 · 25 citations